23
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Role of gastrointestinal endoscopy in the screening of digestive tract cancers in Europe: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary of statements

          In Europe at present, but also in 2040, 1 in 3 cancer-related deaths are expected to be caused by digestive cancers. Endoscopic technologies enable diagnosis, with relatively low invasiveness, of precancerous conditions and early cancers, thereby improving patient survival. Overall, endoscopy capacity must be adjusted to facilitate both effective screening programs and rigorous control of the quality assurance and surveillance systems required.

          1 For average-risk populations, ESGE recommends the implementation of organized population-based screening programs for colorectal cancer, based on fecal immunochemical testing (FIT), targeting individuals, irrespective of gender, aged between 50 and 75 years. Depending on local factors, namely the adherence of the target population and availability of endoscopy services, primary screening by colonoscopy or sigmoidoscopy may also be recommendable.

          2 In high-risk populations, endoscopic screening for gastric cancer should be considered for individuals aged more than 40 years. Its use in countries/regions with intermediate risk may be considered on the basis of local settings and availability of endoscopic resources.

          3 For esophageal and pancreatic cancer, endoscopic screening may be considered only in high-risk individuals:

          – For squamous cell carcinoma, in those with a personal history of head/neck cancer, achalasia, or previous caustic injury;

          – For Barrett’s esophagus (BE)-associated adenocarcinoma, in those with long-standing gastroesophageal reflux disease symptoms (i. e., > 5 years) and multiple risk factors (age ≥ 50 years, white race, male sex, obesity, first-degree relative with BE or esophageal adenocarcinoma [EAC]).

          – For pancreatic cancer screening, endoscopic ultrasound may be used in selected high-risk patients such as those with a strong family history and/or genetic susceptibility.

          Related collections

          Author and article information

          Journal
          Endoscopy
          Endoscopy
          Georg Thieme Verlag KG
          0013-726X
          1438-8812
          March 25 2020
          April 2020
          February 12 2020
          April 2020
          : 52
          : 04
          : 293-304
          Affiliations
          [1 ]Research Center of Gastroenterology and Hepatology Craiova, University of Medicine and Pharmacy, Craiova, Romania
          [2 ]Gastroenterology Department, Regina Maria-Ponderas Academic Hospital, Bucharest, Romania
          [3 ]Nuovo Regina Margherita Hospital, Rome, Italy
          [4 ]Gastroenterology Department, Portuguese Oncology Institute of Coimbra, Portugal
          [5 ]Center for Research in Health Technologies and Information Systems (CINTESIS), Faculty of Medicine, Porto, Portugal
          [6 ]Department of Gastroenterology, Hepatology and Nutrition, MD Anderson Cancer Center, The University of Texas, Houston, USA
          [7 ]Department of Gastroenterology and Hepatology, Catholic University of Leuven (KUL), TARGID, University Hospitals Leuven, Leuven, Belgium
          [8 ]Private office, Aix-en-Provence, France
          [9 ]Department of Gastroenterology and Hepatology, Cancer Center Amsterdam, Amsterdam University Medical Centers, The Netherlands
          [10 ]Department of Hepato-Gastroenterology, Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
          [11 ]Institute for Liver and Digestive Health, Royal Free Hospital Campus, University College London, UK
          [12 ]Epidemiology and Screening Unit-CPO, University Hospital Città della Salute e della Scienza, Turin, Italy
          [13 ]Editorial Board, Epidemiologia e Prevenzione
          [14 ]III Med Klinik, Klinikum Augsburg, Augsburg, Germany
          [15 ]Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands
          [16 ]Gastroenterology Department, Portuguese Oncology Institute of Porto, Portugal
          [17 ]Gastroenterology Division, Edouard Herriot Hospital, Lyon, France
          Article
          10.1055/a-1104-5245
          32052404
          0ec2a165-b06e-4ded-b8b9-a5e25894b06f
          © 2020
          History

          Comments

          Comment on this article